TFIIIC35 Inhibitors
Chemical inhibitors of TFIIIC35 act through diverse mechanisms to inhibit its function in the transcription initiation complex. Plumbagin can intercalate into DNA, disrupting the DNA-binding activity of TFIIIC35, which is essential for its role in transcription initiation. Actinomycin D also targets DNA but does so by binding directly at the transcription initiation site, thereby blocking TFIIIC35 from accessing its necessary binding regions on the DNA strand. Similarly, Mithramycin A binds to DNA in GC-rich sequences, which could alter the DNA structure in such a way that impedes TFIIIC35 function. Mitoxantrone and Etoposide exert their inhibitory actions by intercalating into DNA and inhibiting topoisomerase II, respectively, leading to DNA breaks and a consequent reduction in the availability of intact DNA templates that TFIIIC35 requires for initiating transcription.
Other inhibitors affect TFIIIC35 by targeting the transcription machinery or related processes. α-Amanitin hinders RNA polymerase II, indirectly affecting TFIIIC35 by curtailing the transcription of genes necessary for its function. DRB inhibits the phosphorylation of RNA polymerase II, essential for the transition from initiation to elongation in transcription, thereby indirectly affecting TFIIIC35's role in transcription complexes. Triptolide, while not as direct, impairs the binding of TFIIIC35 to DNA by inhibiting the transcription factor's function overall. ICRF-193 acts by stabilizing the closed clamp form of topoisomerase II, reducing the availability of relaxed DNA, which is necessary for TFIIIC35 to form initiation complexes. Trichostatin A inhibits histone deacetylases, leading to a more open chromatin structure that can disrupt the normal function of TFIIIC35. Finally, Chloroquine disrupts TFIIIC35 by altering the pH of intracellular organelles and interfering with protein degradation pathways, which can lead to altered localization of TFIIIC35, ultimately inhibiting its function in transcription initiation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Plumbagin | 481-42-5 | sc-253283 sc-253283A | 100 mg 250 mg | $52.00 $62.00 | 6 | |
Plumbagin can inhibit TFIIIC35 by interfering with DNA-binding activity due to its ability to intercalate into DNA, potentially disrupting the binding of TFIIIC35 to DNA, which is essential for its role in transcription initiation complex formation. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-amanitin inhibits RNA polymerase II, which in turn can inhibit TFIIIC35 by preventing the transcription of genes that rely on RNA polymerase II, indirectly affecting the protein's availability and function in the transcription initiation complexes. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D can inhibit TFIIIC35 by binding to DNA at the transcription initiation site, thereby preventing the access of transcription initiation factors like TFIIIC35 to their necessary binding sites on DNA, inhibiting the formation of transcription complexes. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide has been shown to inhibit the activity of multiple transcription factors. It can inhibit TFIIIC35 by impairing the transcription factor's function, including the binding to DNA, which is critical for its role in assembling the transcription initiation complex. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB can inhibit TFIIIC35 by inhibiting RNA polymerase II phosphorylation, which is necessary for the transition from transcription initiation to elongation, indirectly affecting the assembly and stability of transcription complexes involving TFIIIC35. | ||||||
ICRF-193 | 21416-68-2 | sc-200889 sc-200889A | 1 mg 5 mg | $341.00 $927.00 | 7 | |
ICRF-193 can inhibit TFIIIC35 by stabilizing the closed clamp form of topoisomerase II, which can lead to the inhibition of transcription initiation involving TFIIIC35 due to the reduced availability of relaxed DNA templates necessary for the initiation complex. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide can inhibit TFIIIC35 by forming a ternary complex with DNA and topoisomerase II, leading to DNA breaks. This can inhibit the function of transcription initiation factors like TFIIIC35 by reducing the availability of intact DNA templates for transcription initiation. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin can inhibit TFIIIC35 by inhibiting topoisomerase I, causing DNA damage which can lead to the inhibition of transcription initiation, thus indirectly inhibiting the function of TFIIIC35 in the formation of transcription initiation complexes. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone can inhibit TFIIIC35 by intercalating into DNA and inhibiting topoisomerase II, which can lead to DNA breaks and inhibition of transcription initiation processes where TFIIIC35 is involved. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A can inhibit TFIIIC35 by binding to DNA in GC-rich sequences, potentially inhibiting the binding and function of TFIIIC35 in the transcription initiation complex by altering the DNA structure and accessibility. | ||||||